Leerink Partnrs Analysts Cut Earnings Estimates for Insulet

Insulet Co. (NASDAQ:PODD) – Investment analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Insulet in a report issued on Thursday, February 20th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will earn $0.65 per share for the quarter, down from their prior estimate of $0.69. The consensus estimate for Insulet’s current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet’s FY2027 earnings at $6.89 EPS, FY2028 earnings at $8.41 EPS and FY2029 earnings at $9.87 EPS.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%.

Other analysts have also recently issued reports about the company. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price target (up from $294.00) on shares of Insulet in a research note on Friday. Stifel Nicolaus upped their price target on Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research note on Friday. Barclays upped their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. BTIG Research upped their price target on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Piper Sandler upped their price target on Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research note on Friday. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $289.06.

Insulet Stock Performance

Shares of PODD stock opened at $282.80 on Monday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market cap of $19.84 billion, a PE ratio of 48.84, a price-to-earnings-growth ratio of 3.62 and a beta of 1.23. The stock has a 50-day moving average of $272.98 and a 200-day moving average of $247.87. Insulet has a one year low of $160.19 and a one year high of $289.46.

Hedge Funds Weigh In On Insulet

Large investors have recently bought and sold shares of the company. QRG Capital Management Inc. acquired a new position in Insulet during the 3rd quarter worth approximately $297,000. Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Insulet by 30.1% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock valued at $2,192,000 after buying an additional 1,942 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after buying an additional 3,113 shares during the last quarter. Orion Portfolio Solutions LLC boosted its holdings in shares of Insulet by 86.2% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock valued at $1,822,000 after buying an additional 3,623 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in shares of Insulet by 5.7% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock valued at $35,708,000 after buying an additional 8,301 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.